In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TaiGen Biotechnology Co. Ltd.

www.taigenbiotech.com

Latest From TaiGen Biotechnology Co. Ltd.

BioLineRx's CXCR4 Antagonist: Promising For Stem Cell Mobilization And AML

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.

Clinical Trials Cancer

Pipeline Watch: Kisqali, SI-6603, Cosentyx Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

China Direct-Acting HCV Drug Race Rapidly Gathering Pace

After the recent approval of its first all-oral hepatitis C regimen, the China FDA is striving to approve within a year more direct-acting antiviral (DAA) therapies to treat all genotypes of the disease, setting the stage for both multinational and domestic pharma firms to compete in the world’s largest HCV drug market.

China Approvals

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • TaiGen Biopharmaceuticals Holdings Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Taiwan
  • Parent & Subsidiaries
  • TaiGen Biotechnology Co. Ltd.
  • Senior Management
  • Ming-Chu Hsu, PhD, Chmn., Pres. & CEO
    Angel Hsiao, Sr. Dir., Fin.
    Philip Kuo-Lung Huang, CCO & SVP, Product Dev. & Mktg. General Mgr.
    Peter Tsao, PhD, VP, Corp. Dev.
    Richard King Chi-Hsin, PhD, SVP, Rsch.
    Edward Kuo, MD, PhD, VP, Clinical Dev.
  • Contact Info
  • TaiGen Biotechnology Co. Ltd.
    Phone: (886) 2 81777072
    7F,138 Shin Ming Rd.
    Neihu Dist.
    Taipei, 114 ROC
    Taiwan
Advertisement
Advertisement
UsernamePublicRestriction

Register